Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
Antimicrobial Agents and Chemotherapy, 05/31/2012
Garrido C et al. – Susceptibility to RAL and EVG is rarely affected in the absence of primary integrase resistance mutations. There is broad cross–resistance between RAL and EVG, which should preclude their sequential use. Resistance to EVG seems to be more frequent and might be more influenced by integrase variability.